文献速递肥胖与代谢综合征

PNPLA3-I148M变异在胰岛素抵抗患者中赋予抗动脉粥样硬化血脂谱

The PNPLA3-I148M Variant Confers an Antiatherogenic Lipid Profile in Insulin-resistant Patients.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

横断面研究比较两个队列中PNPLA3-I148M对血脂和脂蛋白的影响。在胰岛素抵抗且纯合携带者中,该变异显著降低VLDL和LDL颗粒及其成分,升高HDL颗粒及其成分,效应与胰岛素抵抗几何相反。结论认为PNPLA3-I148M尤其在胰岛素抵抗个体中赋予抗动脉粥样硬化血脂谱。

要点

  • PNPLA3-I148M携带者肝脂含量显著高于非携带者。
  • 胰岛素抵抗且纯合携带者中VLDL和LDL颗粒及成分降低,HDL升高。
  • 效应在低胰岛素抵抗者中不可测,非肥胖队列效应较小但仍显著。

核心结论

  • PNPLA3-I148M尤其在胰岛素抵抗个体中赋予抗动脉粥样硬化血脂谱。

研究设计与样本

  • 横断面研究,两个队列按rs738409-G等位基因携带状态和HOMA-IR中位数分组。
  • 减重手术队列298例肥胖患者,年龄49±9岁,BMI 43.2±6.8 kg/m2。
  • 非减重队列345例较不肥胖志愿者,年龄45±14岁,BMI 29.7±5.7 kg/m2。

主要发现

  • 两个队列中PNPLA3-I148M携带者肝脂含量均显著高于非携带者。
  • 胰岛素抵抗且纯合携带者中VLDL和LDL颗粒及成分降低,HDL颗粒及成分升高。
  • 携带者VLDL颗粒更小、LDL颗粒更大,变化与胰岛素抵抗效应几何相反。
  • PNPLA3-I148M在低胰岛素抵抗患者中无可测效应。

临床怎么用

  • 对胰岛素抵抗患者评估PNPLA3-I148M可能有助于识别抗动脉粥样硬化血脂谱。

局限性

  • 横断面设计无法确定因果关系。
  • 非肥胖队列中效应较小但仍显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The I148M (rs738409-G) variant in PNPLA3 increases liver fat content but may be protective against cardiovascular disease. Insulin resistance (IR) amplifies the effect of PNPLA3-I148M on liver fat. OBJECTIVE: To study whether PNPLA3-I148M confers an antihyperlipidemic effect in insulin-resistant patients. DESIGN: Cross-sectional study comparing the impact of PNPLA3-I148M on plasma lipids and lipoproteins in 2 cohorts, both divided into groups based on rs738409-G allele carrier status and median HOMA-IR. SETTING: Tertiary referral center. PATIENTS: A total of 298 obese patients who underwent a liver biopsy during bariatric surgery (bariatric cohort: age 49 ± 9 years, body mass index [BMI] 43.2 ± 6.8 kg/m2), and 345 less obese volunteers in whom liver fat was measured by proton magnetic resonance spectroscopy (nonbariatric cohort: age 45 ± 14 years, BMI 29.7 ± 5.7 kg/m2). MAIN OUTCOME MEASURES: Nuclear magnetic resonance profiling of plasma lipids, lipoprotein particle subclasses and their composition. RESULTS: In both cohorts, individuals carrying the PNPLA3-I148M variant had significantly higher liver fat content than noncarriers. In insulin-resistant and homozygous carriers, PNPLA3-I148M exerted a distinct antihyperlipidemic effect with decreased very-low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) particles and their constituents, and increased high-density lipoprotein particles and their constituents, compared with noncarriers. VLDL particles were smaller and LDL particles larger in PNPLA3-I148M carriers. These changes were geometrically opposite to those due to IR. PNPLA3-I148M did not have a measurable effect in patients with lower IR, and its effect was smaller albeit still significant in the less obese than in the obese cohort. CONCLUSIONS: PNPLA3-I148M confers an antiatherogenic plasma lipid profile particularly in insulin-resistant individuals.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Luukkonen PK, Qadri S, Lehtimäki TE, et al. The PNPLA3-I148M Variant Confers an Antiatherogenic Lipid Profile in Insulin-resistant Patients. J Clin Endocrinol Metab. 2021. PMID: 33064150. doi:10.1210/clinem/dgaa729

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。